Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival
Copyright © 2021. Published by Elsevier Ltd..
BACKGROUND: An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC).
AIMS: We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival.
METHODS: Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching.
RESULTS: The 3-months surveillance interval neither reduced the share of patients diagnosed outside the Milano criteria, nor increased their probability to receive curative treatments. The median survival of 6MS patients (55.0 months [45.9-64.0]) was not significantly different from the observed (47.0 months [35.0-58.9]; p = 0.43) and adjusted (44.9 months [33.4-56.4]; p = 0.30) survival of 3MS patients. A propensity score analysis confirmed the absence of a survival advantage for 3MS patients.
CONCLUSIONS: A tightening of surveillance schedule does not increase the diagnosis of early-stage tumors, the feasibility of curative treatments and the survival. Therefore, we should maintain the 6-months interval in the surveillance of viral cirrhotics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 54(2022), 7 vom: 01. Juli, Seite 927-936 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pelizzaro, Filippo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer stage |
|---|
| Anmerkungen: |
Date Completed 29.06.2022 Date Revised 09.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2021.08.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331216450 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331216450 | ||
| 003 | DE-627 | ||
| 005 | 20231225212956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2021.08.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331216450 | ||
| 035 | |a (NLM)34580038 | ||
| 035 | |a (PII)S1590-8658(21)00766-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pelizzaro, Filippo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2022 | ||
| 500 | |a Date Revised 09.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC) | ||
| 520 | |a AIMS: We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival | ||
| 520 | |a METHODS: Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching | ||
| 520 | |a RESULTS: The 3-months surveillance interval neither reduced the share of patients diagnosed outside the Milano criteria, nor increased their probability to receive curative treatments. The median survival of 6MS patients (55.0 months [45.9-64.0]) was not significantly different from the observed (47.0 months [35.0-58.9]; p = 0.43) and adjusted (44.9 months [33.4-56.4]; p = 0.30) survival of 3MS patients. A propensity score analysis confirmed the absence of a survival advantage for 3MS patients | ||
| 520 | |a CONCLUSIONS: A tightening of surveillance schedule does not increase the diagnosis of early-stage tumors, the feasibility of curative treatments and the survival. Therefore, we should maintain the 6-months interval in the surveillance of viral cirrhotics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer stage | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Surveillance interval | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Peserico, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Elia, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Cazzagon, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Francesco Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Vitale, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Giannini, Edoardo G |e verfasserin |4 aut | |
| 700 | 1 | |a Piccinnu, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Rapaccini, Gian Ludovico |e verfasserin |4 aut | |
| 700 | 1 | |a Di Marco, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Caturelli, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Zoli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Sacco, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Cabibbo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Marra, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Mega, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Morisco, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a Gasbarrini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Svegliati-Baroni, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Foschi, Francesco Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Olivani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Masotto, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Nardone, Gerardo |e verfasserin |4 aut | |
| 700 | 1 | |a Raimondo, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Azzaroli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Vidili, Gianpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveri, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Trevisani, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
| 700 | 0 | |a Italian Liver Cancer (ITA.LI.CA) Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Biselli, Maurizio |e investigator |4 oth | |
| 700 | 1 | |a Caraceni, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Garuti, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Gramenzi, Annagiulia |e investigator |4 oth | |
| 700 | 1 | |a Neri, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Santi, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Piscaglia, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Tovoli, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Granito, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Muratori, Luca |e investigator |4 oth | |
| 700 | 1 | |a Benevento, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Dajti, Elton |e investigator |4 oth | |
| 700 | 1 | |a Marasco, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Ravaioli, Federico |e investigator |4 oth | |
| 700 | 1 | |a Cappelli, Alberta |e investigator |4 oth | |
| 700 | 1 | |a Golfieri, Rita |e investigator |4 oth | |
| 700 | 1 | |a Mosconi, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Renzulli, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Imondi, Angela |e investigator |4 oth | |
| 700 | 1 | |a Sartori, Anna |e investigator |4 oth | |
| 700 | 1 | |a Penzo, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Cela, Ester Marina |e investigator |4 oth | |
| 700 | 1 | |a Facciorusso, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Cacciato, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Casagrande, Edoardo |e investigator |4 oth | |
| 700 | 1 | |a Moscatelli, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Pellegatta, Gaia |e investigator |4 oth | |
| 700 | 1 | |a De Matthaeis, Nicoletta |e investigator |4 oth | |
| 700 | 1 | |a Allegrini, Gloria |e investigator |4 oth | |
| 700 | 1 | |a Lauria, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Ghittoni, Giorgia |e investigator |4 oth | |
| 700 | 1 | |a Pelecca, Giorgio |e investigator |4 oth | |
| 700 | 1 | |a Chegai, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Coratella, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Ortenzi, Mariano |e investigator |4 oth | |
| 700 | 1 | |a Missale, Gabriele |e investigator |4 oth | |
| 700 | 1 | |a Inno, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Marchetti, Fabiana |e investigator |4 oth | |
| 700 | 1 | |a Busacca, Anita |e investigator |4 oth | |
| 700 | 1 | |a Cabibbo, Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Cammà, Calogero |e investigator |4 oth | |
| 700 | 1 | |a Di Martino, Vincenzo |e investigator |4 oth | |
| 700 | 1 | |a Rizzo, Giacomo Emanuele Maria |e investigator |4 oth | |
| 700 | 1 | |a Franzè, Maria Stella |e investigator |4 oth | |
| 700 | 1 | |a Saitta, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Sauchella, Assunta |e investigator |4 oth | |
| 700 | 1 | |a Bevilacqua, Vittoria |e investigator |4 oth | |
| 700 | 1 | |a Borghi, Alberto |e investigator |4 oth | |
| 700 | 1 | |a Casadei Gardini, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Conti, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Dall'aglio, Anna Chiara |e investigator |4 oth | |
| 700 | 1 | |a Ercolani, Giorgio |e investigator |4 oth | |
| 700 | 1 | |a Mirici, Federica |e investigator |4 oth | |
| 700 | 1 | |a Campani, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Di Bonaventura, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Gitto, Stefano |e investigator |4 oth | |
| 700 | 1 | |a Coccoli, Pietro |e investigator |4 oth | |
| 700 | 1 | |a Malerba, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Guarino, Maria |e investigator |4 oth | |
| 700 | 1 | |a Brunetto, Maurizia |e investigator |4 oth | |
| 700 | 1 | |a Romagnoli, Veronica |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 54(2022), 7 vom: 01. Juli, Seite 927-936 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:7 |g day:01 |g month:07 |g pages:927-936 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2021.08.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 7 |b 01 |c 07 |h 927-936 | ||